17
0.00%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medinet Co
Its shares trade on Tokyo Stock Exchange under the ticker 2370.T. It has been listed since 8 October 2003. In the fiscal year to 30 September 2025, it reported revenue of ¥810.3m and a net loss of ¥1.36bn. At that date it held total assets of ¥4.25bn and shareholders' equity of ¥3.78bn.
MEDINET Co., Ltd. engages in cell processing business. The company is headquartered in Ota-Ku, Tokyo-To. The company went IPO on 2003-10-08. The company operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. The company also provides comprehensive support services for immune cell therapy.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 8 Oct 2003
- Employees
- 96
- Website
- medinet-inc.co.jp ↗
Leadership
Pay as last reported
- Mr. Yoshiji KimuraChairman of the Board, since 2002
- Mr. Kanenao KubshiroPresident, Representative Director, since 2020
- Mr. Masami OchiaiDirector of Business Administration, Director, since 2018
- Mr. Takashige KondoDirector of Cell Processing Business, Director, since 2018
- Mr. Kunihide IchikawaIndependent Director
- Mr. Takeshi ShinodaIndependent Director
- Mr. Kouichiro YoshinoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medinet Co Ltd operates in the Life Sciences Tools & Services sector with 96 employees.
- The Cell Processing Industry segment supports immune cell therapy from companies and universities.
- The Cellular Medical Products segment focuses on R&D for cellular medical product approvals.
Weaknesses
- Medinet Co Ltd has a limited workforce of 96 employees in the Health Care sector.
- The company's operations are confined to Ota-ku, Tokyo-To, restricting market reach.
- The Cell Processing Industry segment relies on outsourcing for cell processing services.
Opportunities
- The Life Sciences Tools & Services industry shows growth potential in Japan.
- Medinet Co Ltd can expand its Cell Processing Industry segment to new regions.
- The Cellular Medical Products segment has opportunities for new R&D approvals.
Threats
- The Health Care sector faces regulatory challenges in Japan.
- Medinet Co Ltd's small size may limit competitiveness against larger firms.
- The Cell Processing Industry segment depends on clinical trial outsourcing, which is volatile.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.